Alpha¹ by KaimenConfidential

Kaimen Rigor review

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.

Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, Love S, Williams G, Lawrence R, Mcfarlane B, Archer H, Coulthard E, Underwood BR, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Tan T, Williams S, Ashraf A, Brooks DJ, Harrison J, Hinz R, Tadros G, Passmore AP, Ballard C

DOI: 10.1038/s41591-025-04106-7
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-22

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/7b6213f1-9724-4eae-9c54-0572302ac901 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×2−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 24 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on the secondary outcome ADAS-Exec, a cognitive composite score, which is a surrogate for clinical benefit. The paper does not provide evidence that ADAS-Exec is a validated surrogate for long-term clinical outcomes in Alzheimer's disease, nor does it demonstrate target engagement at the tested dose (e.g., PK/PD data showing central GLP-1 receptor engagement). The primary outcome (cerebral glucose metabolism) was negative, and the cognitive effect was not adjusted for multiple comparisons.
“The secondary outcome—score on the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec)—performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03−0.28; unadjusted P = 0.01).”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect size for the secondary outcome ADAS-Exec is a z-score difference of 0.15, which is small and not anchored to a clinically meaningful threshold. The paper acknowledges that the results were not corrected for multiple comparisons and that the study was exploratory. No minimal clinically important difference is provided, and the effect is not presented as clinically material.
“The secondary outcome—score on the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec)—performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03−0.28; unadjusted P = 0.01).”
Find in source
03Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
12.6% does not match the reported count 13/102
“12.6% of patients in the placebo arm”
ResultsFind in source
04Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
1.1% does not match the reported count 1/102
“1.1% of patients in the placebo arm”
ResultsFind in source
05Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The observed cognitive and MRI benefits may indicate a neuroprotective effect of liraglutide.
“the preserved MRI outcomes may be compatible with a possible neuroprotective effect”
Discussion ¶2Find in source

Findings by category

201ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 2b trial is methodologically rigorous with strong scientific premise, clear design, and transparent reporting. The main weakness is the vague data availability statement, which lacks a repository or persistent identifier, and minor imprecisions in p-value reporting and missing reporting guideline reference.

Both reviewers classified the study as interventional (phase 2b RCT). The evaluation covers all eight dimensions; no dimensions were excluded as not applicable. The reviewers agreed on all dimensions except data code availability, where one rated pass and the other warn; the synthesized status is warn based on the lack of a repository or persistent identifier.

Numerical inconsistencies

2 findings · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 2 printed percentages that do not match their own count.

Numeric forensics— values impossible for the reported sample size

PERCENT
12.6% does not match the reported count 13/102
“12.6% of patients in the placebo arm”
ResultsFind in source
PERCENT
1.1% does not match the reported count 1/102
“1.1% of patients in the placebo arm”
ResultsFind in source

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .140 · recomputed p = .139Reviewers 1, 2
Primary outcome difference and CI
“The primary outcome showed no significant differences in cerebral glucose metabolism (difference = −0.17; 95% confidence interval: −0.39 to 0.06; P = 0.14)”
Find in source
Taken as given: The difference is the estimated mean difference from ANCOVA.; The CI is a 95% confidence interval for the difference.; The p-value is two-sided.
Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.
How we recomputed it: pCI(-0.17, -0.39, 0.06, 0)
CONSISTENTreported p = .010 · recomputed p = .019Reviewers 1, 2
ADAS-Exec secondary outcome difference and CI
“The secondary outcome—score on the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec)—performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03−0.28; unadjusted P = 0.01).”
Find in source
Taken as given: The difference is the estimated mean difference from the mixed-effects model.; The CI is a 95% confidence interval for the difference.; The p-value is two-sided.
Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.
How we recomputed it: pCI(0.15, 0.03, 0.28, 0)
CONSISTENTreported p = .650 · recomputed p = .656Reviewers 1, 2
ADCS-ADL secondary outcome difference and CI
“No significant differences were observed in Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) (−0.58; 95% confidence interval: −3.13 to 1.97; unadjusted P = 0.65)”
Find in source
Taken as given: The difference is the estimated mean difference from the mixed-effects model.; The CI is a 95% confidence interval for the difference.; The p-value is two-sided.
Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.
How we recomputed it: pCI(-0.58, -3.13, 1.97, 0)
CONSISTENTreported p = .810 · recomputed p = .816Reviewers 1, 2
CDR-SoB secondary outcome difference and CI
“No significant differences were observed in ... Clinical Dementia Rating-Sum of Boxes (CDR-SoB) (−0.06; 95% confidence interval: −0.57 to 0.44; unadjusted P = 0.81) scores.”
Find in source
Taken as given: The difference is the estimated mean difference from the mixed-effects model.; The CI is a 95% confidence interval for the difference.; The p-value is two-sided.
Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.
How we recomputed it: pCI(-0.06, -0.57, 0.44, 0)

lowinternal contradiction
The Methods state 'We had 101 participants for the analysis using spectral analysis with arterial plasma input, whereas the less invasive SUV method had 154 participants with baseline and 52-week analyzable scans.' This could be interpreted as two different sample sizes for the primary outcome, but the paper explains that SUV was the primary and spectral was sensitivity, so it is not a contradiction.
“We had 101 participants for the analysis using spectral analysis with arterial plasma input, whereas the less invasive SUV method had 154 participants with baseline and 52-week analyzable scans.”
Statistical analysisFind in source
lowinternal contradiction
The abstract states 'Results from the phase ELAD 2 trial' while the main text consistently uses 'phase 2b'. This is a minor inconsistency in trial phase labeling.
“Results from the phase ELAD 2 trial reveal that liraglutide is safe and well tolerated in people with mild to moderate Alzheimer’s disease but does not significantly slow brain metabolism decline.”
AbstractFind in source
lowinternal contradiction
The paper reports 102 participants per group, but the power calculation required 103 per group; this is acknowledged as a limitation.
“Allowing for a dropout of 15% over the study period, the trial required 103 participants per group (206 in total).”
Statistical analysisFind in source
lowinternal contradiction
The abstract states '204 participants' but the power calculation required 206 total; the paper explains this as a slight shortfall.
In this study, we aimed to evaluate the safety and efficacy of liraglutide in mild to moderate Alzheimer’s disease syndrome. 'Evaluating liraglutide in Alzheimer’s disease' (ELAD) is a multicenter, randomized, double-blind, placebo-controlled phase 2b trial in 204 participants with mild to moderate Alzheimer’s disease syndrome with no diabetes.
Abstractreviewer’s wording

Overstated conclusions

4 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 3 only partially supported (evidence backs part of the claim; gaps or caveats remain).

overstatedReviewer 1
The observed cognitive and MRI benefits may indicate a neuroprotective effect of liraglutide.
The paper suggests a neuroprotective effect based on exploratory outcomes, but the primary outcome was negative and the secondary outcomes were not corrected for multiple comparisons, so this claim goes beyond the evidence.
Evidence: Discussion states 'the preserved MRI outcomes may be compatible with a possible neuroprotective effect' and 'we suggest that a neuroprotective effect may be a class effect of GLP-1 analogs.'
“the preserved MRI outcomes may be compatible with a possible neuroprotective effect”
Discussion ¶2Find in source
partialReviewers 1, 2
Liraglutide improves cognitive function as measured by ADAS-Exec.
The ADAS-Exec secondary outcome showed a significant difference, but the authors caution that it was not corrected for multiple comparisons and is exploratory.
Evidence: ADAS-Exec result: 0.15; 95% CI: 0.03−0.28; unadjusted P = 0.01.
“The secondary outcome—score on the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec)—performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03−0.28; unadjusted P = 0.01).”
AbstractFind in source
partialReviewer 1
Liraglutide slows brain volume loss in exploratory analyses.
Exploratory MRI analyses showed significant differences in some regions, but these were exploratory and not corrected for multiple comparisons.
Evidence: Exploratory outcomes: temporal lobe volume reduction 696 mm3; 95% CI: 184.37−1,208.12; P < 0.001; total gray matter 7,274 mm3; 95% CI: 2,704.05−11,844.8; unadjusted P = 0.002.
“the exploratory analyses of liraglutide-treated participants showed lower volume reductions in the temporal lobe (696 mm 3 ; 95% confidence interval: 184.37−1,208.12; P < 0.001) and total gray matter volume (7,274 mm 3 ; 95% confidence interval: 2,704.05−11,844.8; unadjusted P = 0.002) compared to the placebo group”
ResultsFind in source
partialReviewer 2
Liraglutide slows brain volume loss in exploratory MRI analyses.
Exploratory analyses showed significant differences in some regions, but these were not corrected for multiple comparisons and are exploratory.
Evidence: Exploratory MRI results: temporal lobe volume reduction 696 mm3; 95% CI: 184.37−1,208.12; P < 0.001.
However, the exploratory analyses of liraglutide-treated participants showed lower volume reductions in the temporal lobe (696 mm3; 95% confidence interval: 184.37−1,208.12; P < 0.001) and total gray matter volume (7,274 mm3; 95% confidence interval: 2,704.05−11,844.8; unadjusted P = 0.002) compared to the placebo group.
Resultsreviewer’s wording
supportedReviewers 1, 2
Liraglutide is safe and well tolerated in patients with mild to moderate Alzheimer's disease.
The safety data presented (adverse events, serious adverse events) support this claim.
Evidence: Safety results section reports adverse events and serious adverse events, with no significant safety concerns.
“Liraglutide was generally safe and well tolerated in non-diabetic patients with Alzheimer’s disease.”
AbstractFind in source
supportedReviewer 1
Liraglutide does not significantly slow brain metabolism decline as measured by the primary outcome.
The primary outcome showed no significant difference, supporting this claim.
Evidence: Primary outcome result: difference = −0.17; 95% CI: −0.39 to 0.06; P = 0.14.
“The primary outcome showed no significant differences in cerebral glucose metabolism (difference = −0.17; 95% confidence interval: −0.39 to 0.06; P = 0.14)”
AbstractFind in source
supportedReviewer 2
Liraglutide does not significantly slow brain metabolism decline as measured by FDG-PET.
The primary outcome showed no significant difference, supporting this claim.
Evidence: Primary outcome result: difference = −0.17; 95% CI: −0.39 to 0.06; P = 0.14.
“The primary outcome showed no significant differences in cerebral glucose metabolism (difference = −0.17; 95% confidence interval: −0.39 to 0.06; P = 0.14) between the two groups.”
AbstractFind in source

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

INADEQUATESurrogate endpoint
The primary efficacy claim is based on the secondary outcome ADAS-Exec, a cognitive composite score, which is a surrogate for clinical benefit. The paper does not provide evidence that ADAS-Exec is a validated surrogate for long-term clinical outcomes in Alzheimer's disease, nor does it demonstrate target engagement at the tested dose (e.g., PK/PD data showing central GLP-1 receptor engagement). The primary outcome (cerebral glucose metabolism) was negative, and the cognitive effect was not adjusted for multiple comparisons.
“The secondary outcome—score on the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec)—performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03−0.28; unadjusted P = 0.01).”
Find in source
INADEQUATEEffect size
The reported effect size for the secondary outcome ADAS-Exec is a z-score difference of 0.15, which is small and not anchored to a clinically meaningful threshold. The paper acknowledges that the results were not corrected for multiple comparisons and that the study was exploratory. No minimal clinically important difference is provided, and the effect is not presented as clinically material.
“The secondary outcome—score on the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec)—performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03−0.28; unadjusted P = 0.01).”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites numerous preclinical and clinical studies supporting the neuroprotective effects of GLP-1 receptor agonists, including liraglutide, and acknowledges the need for multitargeted therapies. The rationale for the study is logically derived from this evidence, and the authors address limitations of prior research, such as small sample sizes and the need for larger trials.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise with extensive prior work and a clear rationale for testing liraglutide in Alzheimer's disease.

Evidence

“Liraglutide has shown compelling preclinical evidence of influencing multiple targets in transgenic mouse models.”

Introduction ¶1Find in source

“In the ELAD study, we sought to evaluate the influence of liraglutide on the change in cerebral glucose metabolic rate (rCMRglc), cognition and magnetic resonance imaging (MRI) volume from baseline to week 52 in patients with mild to moderate Alzheimer’s disease syndrome.”

IntroductionFind in source

paraphrase[Discussion, paragraph 4]

“This finding differs from a previous 26-week pilot study in which liraglutide prevented a decline in glucose metabolism compared to placebo.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing extensive preclinical and clinical evidence for GLP-1 receptor agonists in Alzheimer's disease, and clearly links this to the study's objectives.

Evidence

“Liraglutide has shown compelling preclinical evidence of influencing multiple targets in transgenic mouse models.”

Introduction ¶1Find in source

IntroductionFind in source

“Due to the exploratory nature of this phase 2b study, these findings need to be confirmed in larger studies.”

Discussion ¶3Find in source

Randomization used stratified block randomization with a fixed block size of six, and blinding is described as double-blind. A power calculation was performed based on prior FDG-PET data, requiring 103 participants per group. Inclusion/exclusion criteria are described, and the analysis population (ITT) and missing data handling (mean imputation for baseline covariates) are specified. The trial is a single pivotal study, so independent replication is not applicable.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with clear randomization, blinding, power analysis, and pre-specified outcomes, though some details on inclusion/exclusion and outlier handling are in supplementary files.

Evidence

“A total of 204 participants were randomized to receive the active drug or placebo with a 1:1 allocation ratio using stratified block randomization with a fixed block size of six.”

MethodsFind in source

“we conducted a 12-month, multicenter, randomized, double-blind, placebo-controlled phase 2b trial”

MethodsFind in source

“82 participants would be required per group to provide 80% power at a 5% significance level.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, power calculation, and pre-specified inclusion/exclusion criteria.

Evidence

“A total of 204 participants were randomized to receive the active drug or placebo with a 1:1 allocation ratio using stratified block randomization with a fixed block size of six.”

MethodsFind in source

“we conducted a 12-month, multicenter, randomized, double-blind, placebo-controlled phase 2b trial”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“Assuming that the treatment reduces the mean change of [18F]FDG SUV in the participants with Alzheimer’s disease to −0.025 (44% effect size), 82 participants would be required per group to provide 80% power at a 5% significance level.”

Sex is reported for both groups. Age is reported. Health status is implied through inclusion criteria (MMSE, CDR) and exclusion of diabetes. Demographics include age, sex, education, and race. Species/strain and housing are not applicable. Sex justification is not applicable as both sexes are enrolled.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, and demographics, though health status is partially covered.

Evidence

“Female sex (38% versus 41%), age (72.5 years versus 70.6 years) and education (12.9 years versus 13.1 years) were balanced in the placebo and treatment groups, respectively.”

Table 1Find in source

“Four participants identified as non-White, and the remainder identified as White.”

ResultsFind in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, education, and cognitive scores.

Evidence

“Female sex (38% versus 41%), age (72.5 years versus 70.6 years) and education (12.9 years versus 13.1 years) were balanced in the placebo and treatment groups, respectively.”

ResultsFind in source

“Four participants identified as non-White, and the remainder identified as White.”

ResultsFind in source

The study was approved by named ethics committees (National Research Ethics Committee-Riverside and Imperial College London/Imperial College Healthcare NHS Trust Joint Research Office) and the MHRA. Written informed consent was obtained from all participants. Regulatory compliance is stated through adherence to ethical principles and approval by the MHRA.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals and consent are clearly documented with named ethics committees and informed consent.

Evidence

“This study was approved by the local and regional Regulatory Ethics Committees (National Research Ethics Committee-Riverside and Imperial College London/Imperial College Healthcare NHS Trust Joint Research Office) and the Medicines and Healthcare products Regulatory Agency (MHRA).”

MethodsFind in source

“Written informed consent was provided by all participants before participation in the trial.”

MethodsFind in source

PASSReviewer 2· 95% conf

The study reports approval by named ethics committees and regulatory bodies, and informed consent was obtained.

Evidence

MethodsFind in source

“Written informed consent was provided by all participants before participation in the trial.”

MethodsFind in source

Liraglutide is named with manufacturer (Novo Nordisk) and dose regimen. Software tools (MATLAB, Stata, FreeSurfer, SPM8) are identified with versions. Antibodies, cell lines, mycoplasma, and organisms are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (liraglutide) is adequately identified with dose and regimen, and software tools are identified.

Evidence

“Participants received once-daily injections of liraglutide or placebo. The study drug was administered as a daily subcutaneous injection, commencing with a dose of 0.6 mg once daily, and the dose was escalated to 1.8 mg within 4 weeks.”

MethodsFind in source

“Statistical analyses were performed using MATLAB version 2020a, and all P values were two-sided.”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (liraglutide) is identified with dose and regimen, and software tools are named.

Evidence

MethodsFind in source

“Participants’ T1 MRI volumetric scans at baseline and 52 weeks were processed using FreeSurfer software 7.4.1”

Statistical analysisFind in source

The paper names statistical tests (ANCOVA, mixed-effects model, t-tests, chi-squared) and reports exact p-values and 95% CIs. Assumptions are handled by design (e.g., ANCOVA for primary outcome). Software is identified. Data presentation includes individual data points in box plots and per-group n. Mathematical plausibility checks were not possible for all values, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are well described with named tests, effect sizes with CIs, and software identified, though some p-values are reported as thresholds.

Evidence

paraphrase[Methods, Statistical analysis]

“An analysis of covariance was undertaken for the primary outcome... A multilevel mixed-effects model was used to interrogate the repeated key secondary outcome measures.”

“The primary outcome showed no significant differences in cerebral glucose metabolism (difference = −0.17; 95% confidence interval: −0.39 to 0.06; P = 0.14)”

AbstractFind in source

“frontal (2.82 × 10 −3 ; 95% confidence interval: 2.10 × 10 −4 to 5.44 × 10 −3 ; unadjusted P < 0.036)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

paraphrase[Methods, Statistical analysis]

“An analysis of covariance was undertaken for the primary outcome... A multilevel mixed-effects model was used to interrogate the repeated key secondary outcome measures”

“The primary outcome showed no significant differences in cerebral glucose metabolism (difference = −0.17; 95% confidence interval: −0.39 to 0.06; P = 0.14)”

AbstractFind in source

The data availability statement says deidentified individual participant data are included in the paper and supplementary data files, but does not provide a repository or persistent identifier. This is reported_but_inadequate. No code sharing is mentioned, but the study may not have bespoke code.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately stated with deidentified participant data included in the paper and supplementary files, and source data provided.

Evidence

“The deidentified individual participant data that underlie the results reported in this paper (including text, tables and figures) are included in the paper and supplementary data files.”

Data availabilityFind in source

WARNReviewer 2· 80% conf

A data availability statement exists but is vague, stating data are included in the paper and supplementary files without a repository or accession.

Evidence

“The deidentified individual participant data that underlie the results reported in this paper (including text, tables and figures) are included in the paper and supplementary data files.”

Data availabilityFind in source

The trial is registered (NCT01843075). Methods are detailed. Limitations are discussed extensively. Conclusions are proportional. Funding and COI are provided. Reporting guideline is not explicitly mentioned, but the paper follows a structured format.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, detailed methods, limitations discussed, and funding/COI statements, though no reporting guideline is explicitly mentioned.

Evidence

“ClinicalTrials.gov identifier: NCT01843075”

AbstractFind in source

“A key limitation of this study was that attrition reduced the achieved sample size compared to that planned in the original power calculation.”

Discussion ¶8Find in source

paraphrase[Acknowledgements and Competing interests]

“Funding for the conduct of the trial was provided by the Alzheimer’s Society... and Novo Nordisk A/S”

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“ClinicalTrials.gov identifier: NCT01843075”

AbstractFind in source

“A key limitation of this study was that attrition reduced the achieved sample size compared to that planned in the original power calculation.”

Discussion ¶8Find in source

Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.

ClinicalTrials.gov

NCT01843075

ClinicalTrials.gov

NCT03439943

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 48 references by DOI: 2 verified — 46 no DOI (shown, not verified).

NO DOI
A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liraglutide protects against brain amyloid-β 1−42 accumulation in female mice with early Alzheimer’s disease-like pathology by partially rescuing oxidative/nitrosative stress and inflammation
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liraglutide and semaglutide: pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A pilot study of exenatide actions in Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Drug repositioning and repurposing for Alzheimer disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Exenatide and the treatment of patients with Parkinson’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the Exenatide-PD Trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Comparative efficacy and acceptability of antidiabetic agents for Alzheimer’s disease and mild cognitive impairment: a systematic review and network meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Blarcamesine for the treatment of early Alzheimer’s disease: results from the ANAVEX2-73-AD-004 phase IIB/III trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Consequences of metabolic disruption in Alzheimer’s disease pathology
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Cortical dysfunction in non-demented Parkinson’s disease patients: a combined 31 P-MRS and 18 FDG-PET study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Spectral analysis of dynamic PET studies
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Measuring cognitive change in Alzheimer’s disease clinical drug trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer’s disease transgenic mice
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
PBT2 rapidly improves cognition in Alzheimer’s disease: additional phase II analyses
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Adjusting for partially missing baseline measurements in randomized trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

1 data/code link checked; 1 live.

datahttp://clinicaltrials.gov/study/NCT01843075LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly typo, consistency, clarity.

MINORtypoAuthor list
“Edison Paul Femminella Grazia Daniela Ritchie Craig Nowell Joseph Holmes Clive Walker Zuzana Ridha Basil Raza Sanara Livingston Nicholas R Frangou Eleni Love Sharon Williams Gareth Lawrence Robert Mcfarlane Brady Archer Hilary Coulthard Elizabeth Underwood Benjamin R Koranteng Paul Karim Salman Bannister Carol Perneczky Robert Prasanna Aparna Junaid Kehinde McGuinness Bernadette Nilforooshan Ramin Macharouthu Ajay Donaldson Andrew Thacker Simon Russell Gregor Malik Naghma Mate Vandana Knight Lucy Kshemendran Sajeev Holscher Christian Mansouri Anita Chester-Jones Mae Holmes Jane Tan Trisha Williams Steve Ashraf Azhaar Brooks David J Harrison John Hinz Rainer Tadros George Passmore Anthony Peter Ballard Clive”
→ Format author names and affiliations properly, likely with commas and line breaks.
The author list appears as a continuous string without proper separation.
MINORconsistencyAbstract
“Results from the phase ELAD 2 trial reveal that liraglutide is safe and well tolerated in people with mild to moderate Alzheimer’s disease but does not significantly slow brain metabolism decline.”
→ Change 'phase ELAD 2' to 'phase 2b ELAD trial' for consistency with the rest of the paper.
The abstract uses 'phase ELAD 2' while the main text uses 'phase 2b'.
MINORclarityMethods, Statistical analysis
“We had 101 participants for the analysis using spectral analysis with arterial plasma input, whereas the less invasive SUV method had 154 participants with baseline and 52-week analyzable scans.”
→ Clarify that the 101 participants are a subset of the 154, or explain the discrepancy.
The sentence could be misinterpreted as two separate groups.
MINORtypoAuthor list
“Edison Paul Femminella Grazia Daniela Ritchie Craig Nowell Joseph Holmes Clive Walker Zuzana Ridha Basil Raza Sanara Livingston Nicholas R Frangou Eleni Love Sharon Williams Gareth Lawrence Robert Mcfarlane Brady Archer Hilary Coulthard Elizabeth Underwood Benjamin R Koranteng Paul Karim Salman Bannister Carol Perneczky Robert Prasanna Aparna Junaid Kehinde McGuinness Bernadette Nilforooshan Ramin Macharouthu Ajay Donaldson Andrew Thacker Simon Russell Gregor Malik Naghma Mate Vandana Knight Lucy Kshemendran Sajeev Holscher Christian Mansouri Anita Chester-Jones Mae Holmes Jane Tan Trisha Williams Steve Ashraf Azhaar Brooks David J Harrison John Hinz Rainer Tadros George Passmore Anthony Peter Ballard Clive”
→ Format author names and affiliations properly.
The author list appears as a single string without proper separation.
MINORconsistencyAbstract
“Results from the phase ELAD 2 trial reveal that liraglutide is safe and well tolerated in people with mild to moderate Alzheimer’s disease but does not significantly slow brain metabolism decline.”
→ Change 'phase ELAD 2' to 'phase 2b ELAD trial' for consistency.
The phrase 'phase ELAD 2' is awkward and inconsistent with the rest of the text.
MINORclarityMethods, Statistical analysis
“We had 101 participants for the analysis using spectral analysis with arterial plasma input, whereas the less invasive SUV method had 154 participants with baseline and 52-week analyzable scans.”
→ Clarify that the 101 participants are a subset of the 154.
The sentence could be misinterpreted as two separate groups.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published paper is robust in design and reporting, but an informed reader should note the vague data availability statement (no repository or persistent identifier) and the minor imprecision in reporting some exploratory p-values as thresholds. These issues do not invalidate the findings but warrant consideration for a correction or independent re-analysis.

1.
HIGHdata code
Deposit deidentified individual participant data in a public repository (e.g., Dryad, Zenodo) with a DOI, or specify a managed access procedure in the Data Availability section.
The current statement is vague and does not meet best practices for data sharing, which could limit reproducibility and trust.
2.
HIGHreporting
In the Results, replace threshold p-values (e.g., 'P < 0.036') with exact p-values for all exploratory outcomes.
Threshold p-values reduce precision and transparency, and exact values are expected for all reported analyses.
3.
HIGHreporting
In the Methods or Acknowledgements, explicitly reference the CONSORT reporting guideline.
Mentioning adherence to a reporting guideline enhances transparency and completeness of reporting.
4.
MEDIUMreporting
In the Methods, move the inclusion/exclusion criteria from supplementary files to the main text.
Key eligibility criteria should be in the main text for easy access and transparency.
5.
MEDIUMreporting
In the Methods, describe how outliers were handled in the statistical analysis, or state that no outliers were excluded.
Outlier handling is a standard reporting element that affects the interpretation of results.
6.
MEDIUMreporting
In the Methods, clarify the relationship between the 101 participants for spectral analysis and the 154 for SUV analysis (e.g., that the 101 are a subset).
The current wording could be misinterpreted as two separate groups, reducing clarity.
7.
MEDIUMcopyedit
In the Abstract, change 'phase ELAD 2' to 'phase 2b ELAD trial' for consistency with the main text.
Inconsistent terminology may confuse readers and suggests a lack of editorial care.
8.
MEDIUMcopyedit
Format the author list with proper separators (commas, line breaks) to avoid a continuous string.
The current formatting is unreadable and unprofessional.
9.
LOWreporting
In the Discussion, explicitly state that secondary outcomes were not corrected for multiple comparisons, and discuss the implications.
This is already mentioned but could be emphasized to avoid overinterpretation of exploratory findings.
10.
LOWreporting
In the Methods, provide more detail on randomization implementation (e.g., who generated the allocation sequence and how it was concealed).
Additional detail would improve reproducibility and trust in the randomization process.
11.
LOWreporting
In the Discussion, expand on the lack of diversity in the sample and its implications for generalizability.
The sample is predominantly White, which limits generalizability; this is already mentioned but could be expanded.
12.
LOWreporting
In the Methods, specify the statistical software used for each analysis (e.g., MATLAB for PET, Stata for clinical outcomes) to improve reproducibility.
Clearer software attribution aids reproducibility.
13.
LOWreporting
In the Methods, clarify the placebo composition and manufacturer for completeness.
Full identification of the placebo is standard for clinical trial reporting.
14.
LOWreporting
If custom analysis code was used, share it in a public repository (e.g., GitHub) with a version and DOI.
Code sharing enhances reproducibility, though the paper may not have bespoke code.

Full text (68,538 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.

DOI

10.1038/s41591-025-04106-7

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-22